Study of folate receptor alpha in ovarian cancer tissue
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at a marker called folate receptor alpha in tissue samples from people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. The goal is to see how common this marker is, which may help guide future treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that has come back after treatment.
- Your cancer was diagnosed as high-grade serous carcinoma.
- You have stored tissue samples from your first diagnosis and from your first recurrence that were collected after January 1, 2016.
- Your doctor confirms that these tissue samples are suitable for testing a specific marker called folate receptor alpha.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines tissue samples from women with a specific type of ovarian cancer (high-grade serous) to measure how much of a protein called folate receptor alpha is present. Understanding this protein level may help doctors identify which patients could benefit from targeted treatments in the future.
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
This study collects tumor samples from people with ovarian, fallopian tube, or peritoneal cancer to look for genetic changes. The goal is to better understand these cancers and potentially guide future treatment decisions.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
This study tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian cancer that has a specific protein (FRα). It's real-world research to see how well the drug works and how it affects people's daily lives.
This study will collect medical information from people with advanced ovarian, peritoneal, or fallopian tube cancer. The goal is to learn more about these cancers and improve future treatments.
Hear when a new Cancer - Ovarian trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.